GSK, Vernalis in cancer deal potentially worth $200M

GlaxoSmithKline agreed to pay Vernalis as much as $200 million, including $6 million upfront, in relation to the biotech firm's cancer research. GSK will oversee preclinical development of compounds from studies and also have an option to license any of those treatments.

View Full Article in:

Wall Street Journal (tiered subscription model), The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Group Health Cooperative
Group Health Cooperative
Seattle, WA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR